Lannett Company, Inc. (LCI) saw a big move last session, as the company’s shares fell over 17% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for LCI, as the stock is down nearly 24% since Jul 2.

This Medical company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings estimate hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

LCI currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Drugs industry include Flamel Technologies SA (FLML), Salix Pharmaceuticals Ltd. (SLXP) and Synergy Pharmaceuticals, Inc. (SGYP). All these stocks carry a Zacks rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

LANNETT COMP (LCI): Free Stock Analysis Report

FLAMEL TECHNOLOGIES ADS (FLML): Free Stock Analysis Report

SALIX PHARMACEUTICALS LTD (SLXP): Free Stock Analysis Report

SYNERGY PHARMACEUTICALS DE (SGYP): Free Stock Analysis Report


Zacks Investment Research